Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
about
Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@en
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@nl
type
label
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@en
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@nl
prefLabel
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@en
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@nl
P2093
P2860
P1433
P1476
Oncogenic activation of JAK3-S ...... atural killer/T-cell lymphoma.
@en
P2093
A Bisconte
B K H Chia
G C Wijaya
J M Bradshaw
M -L Nairismägi
P2860
P2888
P304
P356
10.1038/S41375-017-0004-X
P577
2018-02-02T00:00:00Z
P6179
1100795940